GMEDNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLOBUS MEDICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$75.65−1.06 (-1.38%)
Close on Oct 19, 2026
- Market cap
- $10.39B
- P/E (TTM)
- 19.3
- Dividend yield
- –
GLOBUS MEDICAL INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $789.61M | $759.85M | – | – | $745.34M | $598.12M | – | – | – | – | – | – | 100.0% | +5.9% |
| Musculoskeletal Solutions And Enabling Technologies [Member] | – | – | – | $769.05M | – | – | – | $625.71M | – | – | – | – | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $183.60M | $152.64M | – | – | $76.88M | $97.72M | – | – | – | – | – | – | +138.8% |
| Musculoskeletal Solutions And Enabling Technologies [Member] | – | – | – | $138.90M | – | – | – | $47.53M | – | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Musculoskeletal Solutions | $763.54M | $732.98M | – | – | $710.18M | $575.93M | – | – | – | – | – | – | 96.7% | +7.5% |
| Enabling Technologies | $26.07M | $26.87M | – | – | $35.16M | $22.19M | – | – | – | – | – | – | 3.3% | -25.8% |
| Enabling Technologies [Member] | – | – | – | $28.04M | $35.16M | $22.19M | $46.95M | $38.30M | $36.78M | $31.97M | $32.71M | $27.66M | – | – |
| Neuromonitoring Services [Member] | – | – | – | – | – | – | – | – | – | – | – | $8.52M | – | – |
| Musculoskeletal Solutions [Member] | – | – | – | $741.01M | $710.18M | $575.93M | $610.34M | $587.40M | $592.91M | $574.70M | $583.82M | $355.98M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $619.11M | $604.89M | $665.32M | $617.63M | $600.78M | $483.86M | $521.89M | $495.79M | $499.46M | $482.93M | $490.84M | $309.32M | 78.4% | +3.0% |
| International | $170.51M | $154.97M | $161.10M | $151.42M | $144.56M | $114.26M | $135.40M | $129.92M | $130.23M | $123.74M | $125.69M | $74.32M | 21.6% | +18.0% |
From the segment and revenue-disaggregation notes of Globus Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.